TY - JOUR AU - Agarwal, Archana AU - Sonpavde, Guru PY - 2019 TI - A new subtyping model for residual invasive disease after cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer JF - Translational Andrology and Urology; Vol 8, Supplement 3 (July 16, 2019): Translational Andrology and Urology Y2 - 2019 KW - N2 - Muscle invasive bladder cancer (MIBC) is an aggressive malignancy and half of the patients develop metastatic disease within 2 years, which is generally incurable and leads to early mortality (1). Based on prospective randomized trials, MIBC is treated with cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) (2-4). UR - https://tau.amegroups.org/article/view/23220